GlassScriptPhysician profile
Vipul Desai
NPI 1891960969
$101,136.36
in general payments reported to CMS, 2019-2025
38 companies · $5,823 in 2025
The $5,823 reported for 2025 was more than what 91% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $6,065 · 2021: $14K · 2022: $10K · 2023: $8,984 · 2024: $14K · 2025: $5,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $11K · Education: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,740.00 |
| Food and Beverage | $10,881.78 |
| Education | $997.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $33,116.97 | 2019-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Cumberland Pharmaceuticals, INC. | $18,134.60 | 2019-2025 | Vibativ |
| Paratek Pharmaceuticals, INC. | $13,278.10 | 2019-2025 | Nuzyra |
| Ferring Pharmaceuticals INC. | $5,403.32 | 2022-2025 | Rebyota |
| Gilead Sciences, INC. | $4,563.18 | 2019-2025 | Veklury, Biktarvy |
| Cipla USA INC. | $4,541.47 | 2020-2021 | |
| Tetraphase Pharmaceuticals, INC. | $4,395.88 | 2019-2020 | |
| Allergan, INC. | $2,964.19 | 2019-2020 | |
| Viiv Healthcare Company | $2,931.35 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Abbvie INC. | $2,376.10 | 2021-2025 | Dalvance, Teflaro, Avycaz |
| Insmed, INC. | $1,718.66 | 2019-2025 | Arikayce |
| Smith+Nephew, INC. | $1,499.70 | 2019-2025 | Grafix Pl, Renasys Touch, Grafix |
| Merck Sharp & Dohme LLC | $1,489.28 | 2019-2025 | Zerbaxa, Dificid, Delstrigo |
| Astellas Pharma US INC | $1,432.82 | 2019-2025 | Cresemba, Veozah |
| Shionogi INC | $745.63 | 2021-2024 | Fetroja |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $547.28 | 2021-2025 | Xerava, Xacduro, Zevtera |
| Grt US Holding, INC. | $415.75 | 2021-2022 | |
| Emd Serono, INC. | $234.16 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $169.98 | 2024-2025 | Vowst |
| Pfizer INC. | $160.86 | 2022-2025 | |
| Janssen Biotech, INC. | $139.47 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $131.86 | 2019-2021 | |
| Theratechnologies INC. | $108.28 | 2021 | |
| Osiris Therapeutics INC. | $85.70 | 2019 | |
| Organogenesis INC. | $83.84 | 2020-2022 | |
| Abbott Laboratories | $66.76 | 2021 | |
| Endo Pharmaceuticals INC. | $58.28 | 2020-2021 | |
| Tersera Therapeutics LLC | $54.11 | 2024-2025 | Quzyttir |
| Dynavax Technologies Corporation | $49.49 | 2019-2023 | Heplisav-B |
| Octapharma USA, INC. | $41.37 | 2022 | |
| Napo Pharmaceuticals INC | $40.95 | 2019 | |
| Imbed Biosciences INC. | $35.58 | 2022 | |
| Kci USA, INC. | $31.26 | 2019 | |
| Seqirus USA INC | $25.30 | 2019-2025 | Fluad |
| Tactile Systems Technology INC | $18.89 | 2025 | Flexitouch Plus, Nimbl |
| Convatec INC. | $16.94 | 2022 | |
| Ets Wound Care LLC | $15.02 | 2024 | Mirragen Advanced Wound Matrix |
| Nabriva Therapeutics, Plc | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vipul Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.